Article Text

Download PDFPDF
CASE REPORT
Resistant type II cryoglobulinaemic vasculitis successfully treated with bortezomib in a patient with SLE
  1. Katherine Dutton1,5,
  2. Sinisa Savic1,5,
  3. Roger Owen2 and
  4. Edward Vital1,3,5
  1. 1 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
  2. 2 Department of Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  3. 3 National Institute of Health Research Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, UK
  4. 5 Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds, UK
  1. Correspondence to Dr Edward Vital, E.M.J.Vital{at}leeds.ac.uk

Abstract

We report an interesting case of hepatitis C virus-negative type II cryoglobulinaemic vasculitis (CV) in a patient with a background history of systemic lupus erythematosus. The type II CV became less responsive to traditional treatments over time and culminated in an intensive care unit admission with critical multiorgan failure. A detailed flow cytometric evaluation of the bone marrow proved to be helpful in treatment. It demonstrated that bortezomib was a viable alternative treatment option for the type II CV. The patient received bortezomib and has made a full and durable recovery.

  • connective tissue disease
  • vasculitis
  • systemic lupus erythematosus
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors KD: interviewed the patient and constructed the initial and final drafts of the written piece. EV: provided direct clinical care in the case and edited the article. SS and RO: provided direct clinical care and edited the article.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.